

---



---

**LIST OF FIGURES**


---



---

<b>Chapter No.</b>	<b>Figure No.</b>	<b>Title of Figure</b>	<b>Page No.</b>
<b>2</b>	<b>2.1</b>	Structure of Healthy bone.	15
	<b>2.2</b>	Difference between structure of normal and osteoporosis bone	18
	<b>2.3</b>	Pathophysiology of osteoporosis	19
	<b>2.4</b>	Structure of human skin	38
	<b>2.5</b>	Schematic diagram of pathways for drug absorption via the skin	39
<b>3</b>	<b>3.1</b>	Calibration curve of Atorvastatin in methanol	71
	<b>3.2</b>	Calibration of Atorvastatin in phosphate buffer pH 7.4	73
	<b>3.3</b>	Calibration curve of ATO in PBS pH 5.5	75
	<b>3.4</b>	Calibration curve of ATO by RP-HPLC	78
	<b>3.5</b>	Overlay plot of ATO in RP-HPLC	78
	<b>3.6</b>	Calibration curve of ATO in plasma by HPLC	81
	<b>3.7</b>	Overlay plot of ATO in plasma by HPLC	82
	<b>3.8</b>	Calibration curve of Risedronate sodium in distilled water	85
	<b>3.9</b>	Calibration curve of RSNa by RP-HPLC	87
	<b>3.10</b>	Overlay plot of RSNa by RP-HPLC	87
	<b>3.11</b>	Calibration curve of RSNa in plasma	90

	<b>3.12</b>	Overlay plot of RSNa in plasma	90
	<b>4.1</b>	FTIR spectrum of ATO	97
	<b>4.2</b>	FTIR spectrum of RSNa	98
<b>4</b>	<b>4.3(a)</b>	DSC of RSNa	99
	<b>4.3(b)</b>	DSC of ATO	99
	<b>4.4</b>	Drug-Excipient interaction studies by FTIR	100
	<b>5.1</b>	Structure of glycosomes	104
	<b>5.2</b>	FishBone diagram for selection of variables for development of glycosomes	118
	<b>5.3</b>	Model diagnostic plots for vesicle size	132
	<b>5.4</b>	Residual Vs factor plots	134
	<b>5.5</b>	Pipel's plot on response variable 1 (Vesicle size)	134
	<b>5.6</b>	Response surface plot (3D) showing combined effect of independent variables on vesicle size	135
<b>5</b>	<b>5.7</b>	Model diagnostic plots for % EE	139
	<b>5.8</b>	Residuals Vs factor plots for % EE	140
	<b>5.9</b>	Pipel's plot on response of % EE	141
	<b>5.10</b>	Response surface plot (3D) showing combined effect of independent variables on % EE	142
	<b>5.11</b>	Desirability plot for ATO loaded glycosomes a. 3D Desirability plot b. Bar graph of desirability c. Ramp graph of desirability	144
	<b>5.12</b>	Overlay plot for design space	146

	<b>5.13</b>	Analysis of design space	147
	<b>5.14</b>	Vesicle size of ATO loaded glycosomes	149
	<b>5.15</b>	Zeta potential of ATO loaded glycosomes	149
	<b>5.16</b>	TEM photograph of ATO loaded glycosomes (Inset image shows single vesicle)	150
	<b>5.17a</b>	FTIR spectra of Atorvastatin.	151
	<b>5.17b</b>	FTIR spectra of Atorvastatin loaded glycosomes	151
	<b>5.18</b>	Different graph for rheological studies. a. Shear rate Vs shear stress ( $\tau$ ) b. Shear rate Vs Viscosity ( $\eta$ ) c. Logarithmic form of shear rate and viscosity ( $\eta$ )	154
	<b>5.19</b>	Comparison of % cumulative drug release of ATO solution and ATO loaded glycosomes containing different glycerol concentration (0-30% w/w) in (a) pH 5.5 and (b) pH 7.4	157
	<b>5.20</b>	Comparison of % cumulative drug permeation of ATO solution and ATO loaded glycosomes containing different glycerol concentration (0-30% w/w)	161
	<b>5.21</b>	% cell viability study (a) 12 hrs and (b) 24 hrs.	162
	<b>5.22</b>	In vitro cell permeability profile	164
	<b>5.23</b>	Stability study of ATO loaded glycosomes (GLY <sub>30</sub> ) and ATO loaded liposomes (GLY <sub>0</sub> ) at different storage condition	166
	<b>6.1</b>	FishBone diagram for selection of variables for development of glycosomes	182
	<b>6.2</b>	Various model diagnostic plots for vesicle size	194
<b>6</b>	<b>6.3</b>	Residual Vs factor plots	195
	<b>6.4</b>	Pipel's plot on response variable 1	196
	<b>6.5</b>	Response surface plot (3D) showing combined effect of independent variables on vesicle size	196

<b>6.6</b>	Various model diagnostic plots	200
<b>6.7</b>	Residuals Vs each factors plots	201
<b>6.8</b>	Pipel's plot on response variables 2	202
<b>6.9</b>	Response surface plot (3D) showing combined effect of independent variables on % EE	203
<b>6.10</b>	Desirability plot for RSNa loaded glycosomes	205
<b>6.11</b>	Overlay plot for design space	208
<b>6.12</b>	Analysis of design space	208
<b>6.13</b>	Vesicle size measurement by zetasizer	210
<b>6.14</b>	Zeta potential analysis by zetasizer	210
<b>6.15</b>	TEM photograph of RSNa loaded glycosomes (Inset image shows single vesicle)	211
<b>6.16</b>	FTIR spectra of RSNa (A) and RSNa loaded glycosomes (B)	212
<b>6.17</b>	Different graph for rheological studies a. Shear rate Vs shear stress ( $\tau$ ) b. Shear rate Vs Viscosity ( $\eta$ ) c. Logarithmic form of shear rate and viscosity ( $\eta$ )	214
<b>6.18</b>	Comparison of % cumulative drug release of RSNa solution and RSNa loaded glycosomes containing different glycerol concentration (0-30% w/w) in (a) pH 5.5 and (b) pH 7.4.	217
<b>6.19</b>	Ex vivo skin permeation profile of RSNa loaded glycosomes	220
<b>6.20</b>	% cell viability study (a) 12 hrs and (b) 24 hrs	222
<b>6.21</b>	In vitro cell permeability profile	223
<b>6.22</b>	Stability study profile of RSNa loaded liposomes (0% w/w glycerol containing) and RSNa loaded glycosomes at 2-8°C (A and D), 25±2°C/65±5 % RH (B and E), 40±2°C/75±5 % RH (C and F).	226

7	7.1	FishBone diagram for selection of variables for development of PECN	239
	7.2	Model diagnostic plots for particle size	250
	7.3	Residual Vs factor plots	251
	7.4	3D surface plot for showing effects of independent factors on particle size and EE	252
	7.5	Model diagnostic plots for % EE	256
	7.6	Residual Vs factor plots	257
	7.7	Desirability plots for ATO loaded PECN	260
	7.8	Overlay plot for design space	263
	7.9	Analysis of design space	263
	7.10	Particle size analysis by zetasizer	265
	7.11	Surface charge analysis by zetasizer	266
	7.12	TEM analysis of ATO loaded PECN	267
	7.13	FTIR spectra of atorvastatin (a) and atorvastatin loaded PECN (b)	268
	7.14	DSC thermogram of ATO and ATO PECN	268
	7.15	X-ray Diffractogram of ATO and ATO-PECN	269
	7.16	In vitro cumulative drug release profile in PBS 5.5 and 7.4	271
	7.17	Ex vivo skin permeation study profile	274
	7.18	% Cell viability study for 12 hrs (a) and 24 Hrs (b)	275
	7.19	In vitro cell permeability profile	276
	7.20	Effect of storage condition on particle size (a) and % assay (b).	277

	<b>8.1</b>	FishBone diagram for selection of variables for development of PECN	291
	<b>8.2</b>	Model diagnostic plots for particle size	301
	<b>8.3</b>	Residual Vs factor plots	302
	<b>8.4</b>	3D surface plot for particle size.	303
	<b>8.5</b>	Model diagnostic plots for % EE	306
	<b>8.6</b>	Residual Vs factor plots	307
	<b>8.7</b>	3D surface plot for showing effects of independent factors on % EE.	309
	<b>8.8</b>	Desirability plot for RSNa loaded PECN	311
	<b>8.9</b>	Overlay plot for design space	313
	<b>8.10</b>	Analysis of design space	313
<b>8</b>	<b>8.11</b>	Particle size analysis by zetasizer	315
	<b>8.12</b>	Zeta potential analysis by zetasizer	315
	<b>8.13</b>	TEM analysis of RSNa PECN	316
	<b>8.14</b>	FTIR spectra of RSNa (A) and RSNa loaded PECN (B)	317
	<b>8.15</b>	DSC thermogram of RSNa and RSNa-PECN	317
	<b>8.16</b>	X-ray Diffractogram of RSNa and RSNa-PECN	318
	<b>8.17</b>	In vitro cumulative drug release profile	320
	<b>8.18</b>	Ex vivo skin permeation profile	323
	<b>8.19</b>	In vitro cell line study	324
	<b>8.20</b>	In vitro cell permeability profile	325
	<b>8.21</b>	Effect of storage condition on particle size (a) and % assay (b).	326

<b>9</b>	<b>9.1</b>	Ex-vivo skin permeation profile of transdermal patches of ATP, ALP and AGP.	360
	<b>9.2</b>	Ex-vivo skin permeation profile of transdermal patches of RTP, RLP and RGP.	362
	<b>9.3</b>	Ex-vivo skin permeation profile of ATO transdermal patches	365
	<b>9.4</b>	Ex-vivo skin permeation profile of RSNa-PECN transdermal patches	367
	<b>9.5</b>	FTIR spectra of treated (B, C, D and E) and non-treated skin (A).	368
	<b>9.6</b>	Microscopic fluorescent images of treated (A, B, C and D) and non-treated skin €	371
	<b>9.7</b>	Histopathological study of skin	373
	<b>9.8 (A)</b>	Stability study of ATO loaded glycerosomal transdermal patch	375
	<b>9.8 (B)</b>	Stability study of RSNa loaded glycerosomal transdermal patch	376
	<b>9.8 (C)</b>	Stability study of ATO-PECN transdermal patch	377
	<b>9.8 (D)</b>	Stability study of RSNa-PECN transdermal patch	378
<b>10</b>	<b>10.1</b>	Bilateral ovariectomy surgery.	390
	<b>10.2</b>	ATO plasma concentration vs time profile	396
	<b>10.3</b>	RSNa plasma concentration vs time profile	400
	<b>10.4</b>	Radiological images of rats with treated, nontreated and disease model.	403
	<b>10.5</b>	Bone samples isolated for analysis	407
	<b>10.6</b>	Change in bone density after treatment	407
	<b>10.7</b>	Serum calcium (a) and phosphate (b) level	409
	<b>10.8.1</b>	Histopathological photomicrograph of femur bone samples from the normal group and the OVX group	413

<b>10.8.2</b>	Histopathological photomicrograph of femur bone samples from the ATO loaded formulations treated group	414
<b>10.8.3</b>	Histopathological photomicrograph of femur bone samples from the RSNa loaded formulations treated group	415